Targeted therapies for gastric cancer: Failures and hopes from clinical trials

Maria Apicella, Simona Corso, Silvia Giordano

Research output: Contribution to journalReview articlepeer-review


Gastric cancer is the third leading cause of cancer mortality worldwide. As surgery is the only curative treatment strategy and conventional chemotherapy has shown limited efficacy -with a median overall survival of 10 months- new treatments are urgently needed. Trastuzumab and Ramucirumab (targeting HER2 and VEGFR2, respectively) are the only targeted therapies approved so far. Indeed, most Phase III clinical trials evaluating molecular drugs in gastric cancer failed. This review will retrace the relevant clinical trials with molecular therapies performed in gastric cancer patients, discussing the possible reasons for their failure and indicating new perspective for a real improvement of the treatment of this disease.

Original languageEnglish
Pages (from-to)57654-57669
Number of pages16
Issue number34
Publication statusPublished - Jan 1 2017


  • Gastric cancer clinical trials
  • HER2
  • Immunotherapy
  • Targeted therapies
  • Tyrosine kinase receptors

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Targeted therapies for gastric cancer: Failures and hopes from clinical trials'. Together they form a unique fingerprint.

Cite this